Page#: 1  2  3  4  5  6 


InvestSource Inc.: Lev Pharmaceuticals Acquired by ViroPharma
Jul 16, 2008
www.tradingmarkets.com
Lev Pharmaceuticals, Inc. (OTC BB: LEVP | Quote | Chart | News | PowerRating) and ViroPharma Incorporated today announced that the companies have signed a definitive merger agreement under which ViroPharma will acquire Lev, a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases, for $442.9 million of upfront consideration, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock (subject to a collar). ...more


Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Jul 15, 2008
www.rxtimes.com
BASINGSTOKE, England and CAMBRIDGE, Massachusetts, July 15 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, notes that Jerini AG (FSE:JI4) has announced today that the European Commission has granted the company marketing authorization for its lead compound FIRAZYR(R) (Icatibant) in the treatment of acute attacks of hereditary angioedema (HAE). HAE is a debilitating and potentially life-threatening genetic disease characterized by spontaneous and recurring attacks of edema. ...more


Pharming says ongoing open-label studies with Rhucin show positive results
Jul 11, 2008
www.forbes.com
Biotech company Pharming Group N.V. said that its ongoing open-label studies with lead product Rhucin are showing positive results. ...more


Shire Buys Germany's Jerini to Add Rare Disease Drug
Jul 03, 2008
www.bloomberg.com
uly 3 (Bloomberg) -- Shire Ltd., the U.K.'s third-biggest drugmaker, agreed to pay 349 million euros ($554 million) in cash for Germany's Jerini AG to add a treatment for a sometimes fatal tissue swelling. ...more


Lev to file application for approval of angioedema drug
Jul 01, 2008
www.tradingmarkets.com
Pharmaceuticals has entered into a letter agreement with the Sanquin Blood Supply Foundation, authorizing Lev to file for European marketing authorization of its lead product candidate, Cinryze, for the treatment of hereditary angioedema, also known as C1 inhibitor deficiency. ...more


Dyax Announces Final Patient Treated in Second Phase 3 Clinical Trial (EDEMA4®) of DX-88 in Hereditary Angioedema
Jun 23, 2008
www.businesswire.com
Dyax Corp. (NASDAQ: DYAX) announced today that it has treated the final patient in its second Phase 3, 96-patient trial of DX-88, known as EDEMA4, for the treatment of acute attacks of hereditary angioedema (HAE). HAE is a rare and life-threatening inflammatory condition for which there is no approved therapy in the United States. ...more


Jerini to Submit Complete Response to the FDA for Icatibant in the Treatment of HAE
Jun 23, 2008
www.ad-hoc-news.de
Jerini AG (FSE:JI4) announced today that following last week's communication with the US Food and Drug Administration (FDA), the company will submit a complete response to the FDA's not approvable letter for Icatibant in the treatment ofacute attacks of hereditary angioedema (HAE). Jerini's complete response, to be submitted in the next three to four months, will provide the agency with information relating to Icatibant's efficacyin the treatment of HAE. "The FDA has outlined specific areas of concern, which we areplanning to address fully in our complete response," said JensSchneider-Mergener, CEO of Jerini. "Having received very positive feedback from HAE-treating physicians in Europe, Jerini is wellprepared for Icatibant's expected third quarter European product launch ...more


UPDATE 1-Pharming says new test results Rhucin positive
Jun 16, 2008
uk.reuters.com
Dutch biotechnology firm Pharming (PHAR.AS: Quote, Profile, Research) said on Monday safety and efficacy results from a north American trial with its key drug Rhucin were positive, igniting 53 percent rally in its shares. ...more


Lev Pharmaceuticals Signs Agreements with CuraScript, CVS Caremark, and FFF Enterprises to Support Cinryze™ Commercialization
Jun 05, 2008
www.businesswire.com
Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTCBB:LEVP) announced today that it has entered into multi-year agreements with CuraScript, CVS Caremark, and FFF Enterprises to serve as its specialty pharmacy, specialty distribution and patient services partners to support the U.S. commercialization of Cinryze™ [C1 inhibitor, (human)], the company’s investigational treatment for hereditary angioedema (HAE), also known as C1 inhibitor deficiency. ...more


Lev Pharmaceuticals Announces Cinryze(TM) Complete Response Submission Accepted for Review by FDA
May 06, 2008
www.foxbusiness.com
Lev Pharmaceuticals, Inc. (OTCBB: LEVP.OB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Lev's complete response submission for Cinryze(TM: 98.89, -1.59, -1.58%) (C1 inhibitor), the Company's lead product candidate. Lev is seeking marketing approval for Cinryze(TM: 98.89, -1.59, -1.58%) for both the acute and prophylactic treatment of hereditary angioedema (HAE: 55.42, -0.24, -0.43%), also known as C1 inhibitor deficiency. ...more


Page #: 1  2  3  4  5  6